<p>SiBone（纳斯达克代码：SIBN - 获取免费报告）在周四的午盘交易中创下了 52 周的新高，此前 Truist Financial 将该股票的目标价从 21.00 美元上调至 23.00 美元。Truist Financial 目前对该股票给予买入评级。SiBone 的交易最高达到 20.27 美元，最后交易价格为 20.25 美元，成交量为 731079 股。该股票此前收盘价为 19.14 美元。</p>
<ul>
<li>4 个最近的盈利赢家在 5 月迎来新动力</li>
</ul>
<p>其他一些分析师也对该公司进行了评论。摩根士丹利在 12 月 2 日的研究报告中将 SiBone 的目标价从 20.00 美元上调至 23.00 美元，并给予该股票 “超配” 评级。Needham &amp; Company LLC 在周二将 SiBone 的目标价从 24.00 美元上调至 27.00 美元，并给予该股票 “买入” 评级。Canaccord Genuity Group 在周三将 SiBone 的目标价从 26.00 美元上调至 27.00 美元，并给予该公司 “买入” 评级。最后，Weiss Ratings 在周一的研究报告中重申了对 SiBone 的 “卖出（e+）” 评级。五位股票研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 25.00 美元。</p>
<p><strong>获取我们对 SIBN 的最新分析</strong></p>
<h2>SiBone 的内部交易</h2>
<p>在其他 SiBone 的新闻中，董事 Jeffrey W. Dunn 在 12 月 8 日的交易中出售了 18759 股 SiBone 股票。该股票的平均售价为 19.33 美元，总交易额为 362611.47 美元。出售完成后，该董事持有公司股票 110115 股，价值约为 2128522.95 美元。此次交易使其持股减少了 14.56%。该出售在向 SEC 的法律文件中披露，您可以通过此链接访问。此外，首席执行官 Laura Francis 在 11 月 18 日的交易中出售了 5411 股公司股票。该股票的平均售价为 17.70 美元，总价值为 95774.70 美元。出售完成后，首席执行官持有公司股票 351319 股，价值约为 6218346.30 美元。这代表其持股减少了 1.52%。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共出售了 147128 股公司股票，价值 2698252 美元。4.00% 的股票目前由公司内部人士持有。</p>
<h2>机构投资者对 SiBone 的看法</h2>
<p>几家对冲基金最近增加或减少了对 SIBN 的持股。先锋集团在第一季度将 SiBone 的持股增加了 1.5%。先锋集团目前持有 2444159 股公司股票，价值 34292000 美元，此前在上个季度购买了 35349 股。景顺公司在第一季度将 SiBone 的持股增加了 82.8%。景顺公司目前持有 31448 股公司股票，价值 441000 美元，此前在此期间购买了 14245 股。Nuveen LLC 在第一季度购买了 SiBone 的新头寸，价值 18605000 美元。罗素投资集团在第一季度将 SiBone 的持股增加了 765.3%。罗素投资集团目前持有 201758 股公司股票，价值 2831000 美元，此前在此期间购买了 178442 股。最后，美国世纪公司在第一季度将 SiBone 的持股增加了 11.1%。美国世纪公司目前持有 2642322 股公司股票，价值 37072000 美元，此前在此期间购买了 264254 股。98.11% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>SiBone 股票表现</h2>
<p>该公司的速动比率为 6.62，流动比率为 7.97，债务与股本比率为 0.21。该公司的市值为 8.7865 亿美元，市盈率为-39.71，贝塔值为 0.76。该公司的 50 日移动平均价格为 17.22 美元，200 日移动平均价格为 16.84 美元。</p>
<p>SiBone（纳斯达克代码：SIBN - 获取免费报告）在 11 月 10 日最后发布了季度财报。该公司报告本季度每股收益为（0.11 美元），超出市场共识预期的（0.16 美元）0.05 美元。该公司本季度的收入为 4866 万美元，而分析师预期为 4667 万美元。SiBone 的股本回报率为-12.86%，净利润率为-11.24%。研究分析师预测 SiBone 在当前财年将发布-0.78 美元的每股收益。</p>
<h2>SiBone 公司简介</h2>
<p>（获取免费报告）</p>
<p>SI-BONE, Inc 是一家医疗设备公司，致力于解决美国及国际上骶骨盆解剖的肌肉骨骼疾病。它提供专有的微创外科植入系统，以解决骶髂关节功能障碍和融合、成人畸形和退化以及骨盆创伤；以及可植入的骨产品。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 SiBone</li>
<li>国会股票交易跟踪</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>投资者需要了解的击败市场的信息</li>
<li>忘掉芯片：AI 反弹的 4 个工业投资机会</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>MongoDB 可能创下新高——但您需要迅速行动</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 SiBone 吗？</h2>
<p>在考虑 SiBone 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 SiBone 并不在名单上。</p>
<p>虽然 SiBone 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SIBN

<p>SiBone（纳斯达克代码：SIBN）股价创下 52 周新高，此前 Truist Financial 将其目标价从 21 美元上调至 23 美元，并维持买入评级。其他分析师也提高了他们的目标价，推动了股价的上涨。内部销售和机构投资受到关注，98.11% 的股票由对冲基金和机构投资者持有。SiBone 报告的季度收益好于预期，但净资产收益率和净利润率为负。该公司专注于肌肉骨骼疾病的医疗设备</p>

<p>Shares of SiBone (NASDAQ:SIBN - Get Free Report) reached a new 52-week high during mid-day trading on Thursday after Truist Financial raised their price target on the stock from $21.00 to $23.00. Truist Financial currently has a buy rating on the stock. SiBone traded as high as $20.27 and last traded at $20.25, with a volume of 731079 shares trading hands. The stock had previously closed at $19.14.</p>
<div class="lb-trans"><p>SiBone（纳斯达克代码：SIBN - 获取免费报告）在周四的午盘交易中创下了 52 周的新高，此前 Truist Financial 将该股票的目标价从 21.00 美元上调至 23.00 美元。Truist Financial 目前对该股票给予买入评级。SiBone 的交易最高达到 20.27 美元，最后交易价格为 20.25 美元，成交量为 731079 股。该股票此前收盘价为 19.14 美元。</p>
</div><ul>
<li>4 Recent Earnings Winners Riding Fresh Momentum in May</li>
</ul>
<div class="lb-trans"><ul>
<li>4 个最近的盈利赢家在 5 月迎来新动力</li>
</ul>
</div><p>A number of other analysts have also recently commented on the company. Morgan Stanley upped their price target on shares of SiBone from $20.00 to $23.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, December 2nd. Needham &amp; Company LLC upped their target price on shares of SiBone from $24.00 to $27.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday. Canaccord Genuity Group lifted their price target on shares of SiBone from $26.00 to $27.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday. Finally, Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of SiBone in a research note on Monday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $25.00.</p>
<div class="lb-trans"><p>其他一些分析师也对该公司进行了评论。摩根士丹利在 12 月 2 日的研究报告中将 SiBone 的目标价从 20.00 美元上调至 23.00 美元，并给予该股票 “超配” 评级。Needham &amp; Company LLC 在周二将 SiBone 的目标价从 24.00 美元上调至 27.00 美元，并给予该股票 “买入” 评级。Canaccord Genuity Group 在周三将 SiBone 的目标价从 26.00 美元上调至 27.00 美元，并给予该公司 “买入” 评级。最后，Weiss Ratings 在周一的研究报告中重申了对 SiBone 的 “卖出（e+）” 评级。五位股票研究分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “适度买入”，平均目标价为 25.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on SIBN</strong></p>
<div class="lb-trans"><p><strong>获取我们对 SIBN 的最新分析</strong></p>
</div><h2>Insider Transactions at SiBone</h2>
<div class="lb-trans"><h2>SiBone 的内部交易</h2>
</div><p>In other SiBone news, Director Jeffrey W. Dunn sold 18,759 shares of SiBone stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $19.33, for a total transaction of $362,611.47. Following the completion of the sale, the director owned 110,115 shares of the company's stock, valued at approximately $2,128,522.95. The trade was a 14.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Laura Francis sold 5,411 shares of the company's stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $17.70, for a total value of $95,774.70. Following the completion of the sale, the chief executive officer owned 351,319 shares in the company, valued at approximately $6,218,346.30. This represents a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 147,128 shares of company stock worth $2,698,252. 4.00% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 SiBone 的新闻中，董事 Jeffrey W. Dunn 在 12 月 8 日的交易中出售了 18759 股 SiBone 股票。该股票的平均售价为 19.33 美元，总交易额为 362611.47 美元。出售完成后，该董事持有公司股票 110115 股，价值约为 2128522.95 美元。此次交易使其持股减少了 14.56%。该出售在向 SEC 的法律文件中披露，您可以通过此链接访问。此外，首席执行官 Laura Francis 在 11 月 18 日的交易中出售了 5411 股公司股票。该股票的平均售价为 17.70 美元，总价值为 95774.70 美元。出售完成后，首席执行官持有公司股票 351319 股，价值约为 6218346.30 美元。这代表其持股减少了 1.52%。该出售的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共出售了 147128 股公司股票，价值 2698252 美元。4.00% 的股票目前由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On SiBone</h2>
<div class="lb-trans"><h2>机构投资者对 SiBone 的看法</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in SIBN. Vanguard Group Inc. increased its holdings in shares of SiBone by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 2,444,159 shares of the company's stock valued at $34,292,000 after purchasing an additional 35,349 shares in the last quarter. Invesco Ltd. grew its position in SiBone by 82.8% during the first quarter. Invesco Ltd. now owns 31,448 shares of the company's stock valued at $441,000 after buying an additional 14,245 shares during the period. Nuveen LLC purchased a new position in SiBone in the first quarter valued at $18,605,000. Russell Investments Group Ltd. raised its holdings in SiBone by 765.3% in the 1st quarter. Russell Investments Group Ltd. now owns 201,758 shares of the company's stock worth $2,831,000 after purchasing an additional 178,442 shares during the period. Finally, American Century Companies Inc. raised its stake in shares of SiBone by 11.1% during the 1st quarter. American Century Companies Inc. now owns 2,642,322 shares of the company's stock worth $37,072,000 after buying an additional 264,254 shares during the period. 98.11% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近增加或减少了对 SIBN 的持股。先锋集团在第一季度将 SiBone 的持股增加了 1.5%。先锋集团目前持有 2444159 股公司股票，价值 34292000 美元，此前在上个季度购买了 35349 股。景顺公司在第一季度将 SiBone 的持股增加了 82.8%。景顺公司目前持有 31448 股公司股票，价值 441000 美元，此前在此期间购买了 14245 股。Nuveen LLC 在第一季度购买了 SiBone 的新头寸，价值 18605000 美元。罗素投资集团在第一季度将 SiBone 的持股增加了 765.3%。罗素投资集团目前持有 201758 股公司股票，价值 2831000 美元，此前在此期间购买了 178442 股。最后，美国世纪公司在第一季度将 SiBone 的持股增加了 11.1%。美国世纪公司目前持有 2642322 股公司股票，价值 37072000 美元，此前在此期间购买了 264254 股。98.11% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>SiBone Stock Performance</h2>
<div class="lb-trans"><h2>SiBone 股票表现</h2>
</div><p>The company has a quick ratio of 6.62, a current ratio of 7.97 and a debt-to-equity ratio of 0.21. The firm has a market cap of $878.65 million, a PE ratio of -39.71 and a beta of 0.76. The firm has a 50-day moving average price of $17.22 and a two-hundred day moving average price of $16.84.</p>
<div class="lb-trans"><p>该公司的速动比率为 6.62，流动比率为 7.97，债务与股本比率为 0.21。该公司的市值为 8.7865 亿美元，市盈率为-39.71，贝塔值为 0.76。该公司的 50 日移动平均价格为 17.22 美元，200 日移动平均价格为 16.84 美元。</p>
</div><p>SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $48.66 million during the quarter, compared to analysts' expectations of $46.67 million. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%. Research analysts forecast that SiBone will post -0.78 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>SiBone（纳斯达克代码：SIBN - 获取免费报告）在 11 月 10 日最后发布了季度财报。该公司报告本季度每股收益为（0.11 美元），超出市场共识预期的（0.16 美元）0.05 美元。该公司本季度的收入为 4866 万美元，而分析师预期为 4667 万美元。SiBone 的股本回报率为-12.86%，净利润率为-11.24%。研究分析师预测 SiBone 在当前财年将发布-0.78 美元的每股收益。</p>
</div><h2>SiBone Company Profile</h2>
<div class="lb-trans"><h2>SiBone 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.</p>
<div class="lb-trans"><p>SI-BONE, Inc 是一家医疗设备公司，致力于解决美国及国际上骶骨盆解剖的肌肉骨骼疾病。它提供专有的微创外科植入系统，以解决骶髂关节功能障碍和融合、成人畸形和退化以及骨盆创伤；以及可植入的骨产品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than SiBone</li>
<li>Following Congress Stock Trades</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>Earnings Per Share Calculator: How to Calculate EPS</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 SiBone</li>
<li>国会股票交易跟踪</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>投资者需要了解的击败市场的信息</li>
<li>忘掉芯片：AI 反弹的 4 个工业投资机会</li>
<li>每股收益计算器：如何计算 EPS</li>
<li>MongoDB 可能创下新高——但您需要迅速行动</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in SiBone Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 SiBone 吗？</h2>
</div><p>Before you consider SiBone, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 SiBone 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 SiBone 并不在名单上。</p>
</div><p>While SiBone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 SiBone 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

SI-BONE（纳斯达克代码：SIBN）在分析师上调评级后创下新的 12 个月高点